Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: A 12-week study with plasma levels

L. S. Volonteri, A. Colasanti, G. Cerveri, A. Fiorentini, I. F. De Gaspari, M. C. Mauri, A. Valli, P. Papa, C. Mencacci

Research output: Contribution to journalArticle

Abstract

Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor that has been recently approved for the treatment of major depressive disorder (MDD). However, little is known about the relationship between DLX plasma levels and clinical response. The aims of this open-label study were 1) to assess clinical outcome and tolerability of DLX by means of clinician and patient assessments and 2) to evaluate the value of plasma DLX levels as predictors of clinical response and tolerability. This was a naturalistic, open-label study of 45 outpatients affected with MDD (16 men and 29 women), who received DLX at doses of 30-120 mg/day and were evaluated at baseline (T0) and after 2, 4 and 12 weeks (T1-3). The assessments included the Hamilton Rating Scales for Depression (HRSD) and Anxiety (HRSA), Clinical Global Impression-Severity (CGI-S), Beckgs Depression Inventory (BDI) and a mood visual analogue scale (VAS). Compared with T0, there were significant improvements in HRSD at T1, T2 and T3 (P <0.001), in HRSA, CGI-S and the self-administered BDI at T2 and T3 (P <0.001), and in the VAS scores shown at T3 (P = 0.01). DLX treatment was safe and well tolerated. Plasma DLX levels at T2 ranged from 5 to 135 ng/mL (mean ± SD = 53.56 ± 39.45) and correlated almost significantly with the DLX dose (r = 0.35; P = 0.069). There was a significant curvilinear quadratic relationship between the improvement of HRSA scores and plasma DLX levels (R 2 = 0.27; P = 0.02). The incidence of anxiety or irritability was associated with the highest plasma levels. Our findings suggest that monitoring plasma DLX levels may be helpful in predicting better treatment responses and tolerability. The present data seem to suggest an optimal anxiolytic efficacy of DLX at intermediate plasma levels.

Original languageEnglish
Pages (from-to)1193-1199
Number of pages7
JournalJournal of Psychopharmacology
Volume24
Issue number8
DOIs
Publication statusPublished - Aug 2010

Fingerprint

compound A 12
Major Depressive Disorder
Anxiety
Therapeutics
Depression
Visual Analog Scale
Duloxetine Hydrochloride
Equipment and Supplies
Anti-Anxiety Agents
Outpatients

Keywords

  • clinical response
  • duloxetine
  • major depressive disorder
  • plasma levels

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder : A 12-week study with plasma levels. / Volonteri, L. S.; Colasanti, A.; Cerveri, G.; Fiorentini, A.; De Gaspari, I. F.; Mauri, M. C.; Valli, A.; Papa, P.; Mencacci, C.

In: Journal of Psychopharmacology, Vol. 24, No. 8, 08.2010, p. 1193-1199.

Research output: Contribution to journalArticle

@article{ba20a0b1b48749e7ab5af76963ad786b,
title = "Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: A 12-week study with plasma levels",
abstract = "Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor that has been recently approved for the treatment of major depressive disorder (MDD). However, little is known about the relationship between DLX plasma levels and clinical response. The aims of this open-label study were 1) to assess clinical outcome and tolerability of DLX by means of clinician and patient assessments and 2) to evaluate the value of plasma DLX levels as predictors of clinical response and tolerability. This was a naturalistic, open-label study of 45 outpatients affected with MDD (16 men and 29 women), who received DLX at doses of 30-120 mg/day and were evaluated at baseline (T0) and after 2, 4 and 12 weeks (T1-3). The assessments included the Hamilton Rating Scales for Depression (HRSD) and Anxiety (HRSA), Clinical Global Impression-Severity (CGI-S), Beckgs Depression Inventory (BDI) and a mood visual analogue scale (VAS). Compared with T0, there were significant improvements in HRSD at T1, T2 and T3 (P <0.001), in HRSA, CGI-S and the self-administered BDI at T2 and T3 (P <0.001), and in the VAS scores shown at T3 (P = 0.01). DLX treatment was safe and well tolerated. Plasma DLX levels at T2 ranged from 5 to 135 ng/mL (mean ± SD = 53.56 ± 39.45) and correlated almost significantly with the DLX dose (r = 0.35; P = 0.069). There was a significant curvilinear quadratic relationship between the improvement of HRSA scores and plasma DLX levels (R 2 = 0.27; P = 0.02). The incidence of anxiety or irritability was associated with the highest plasma levels. Our findings suggest that monitoring plasma DLX levels may be helpful in predicting better treatment responses and tolerability. The present data seem to suggest an optimal anxiolytic efficacy of DLX at intermediate plasma levels.",
keywords = "clinical response, duloxetine, major depressive disorder, plasma levels",
author = "Volonteri, {L. S.} and A. Colasanti and G. Cerveri and A. Fiorentini and {De Gaspari}, {I. F.} and Mauri, {M. C.} and A. Valli and P. Papa and C. Mencacci",
year = "2010",
month = "8",
doi = "10.1177/0269881109104863",
language = "English",
volume = "24",
pages = "1193--1199",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder

T2 - A 12-week study with plasma levels

AU - Volonteri, L. S.

AU - Colasanti, A.

AU - Cerveri, G.

AU - Fiorentini, A.

AU - De Gaspari, I. F.

AU - Mauri, M. C.

AU - Valli, A.

AU - Papa, P.

AU - Mencacci, C.

PY - 2010/8

Y1 - 2010/8

N2 - Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor that has been recently approved for the treatment of major depressive disorder (MDD). However, little is known about the relationship between DLX plasma levels and clinical response. The aims of this open-label study were 1) to assess clinical outcome and tolerability of DLX by means of clinician and patient assessments and 2) to evaluate the value of plasma DLX levels as predictors of clinical response and tolerability. This was a naturalistic, open-label study of 45 outpatients affected with MDD (16 men and 29 women), who received DLX at doses of 30-120 mg/day and were evaluated at baseline (T0) and after 2, 4 and 12 weeks (T1-3). The assessments included the Hamilton Rating Scales for Depression (HRSD) and Anxiety (HRSA), Clinical Global Impression-Severity (CGI-S), Beckgs Depression Inventory (BDI) and a mood visual analogue scale (VAS). Compared with T0, there were significant improvements in HRSD at T1, T2 and T3 (P <0.001), in HRSA, CGI-S and the self-administered BDI at T2 and T3 (P <0.001), and in the VAS scores shown at T3 (P = 0.01). DLX treatment was safe and well tolerated. Plasma DLX levels at T2 ranged from 5 to 135 ng/mL (mean ± SD = 53.56 ± 39.45) and correlated almost significantly with the DLX dose (r = 0.35; P = 0.069). There was a significant curvilinear quadratic relationship between the improvement of HRSA scores and plasma DLX levels (R 2 = 0.27; P = 0.02). The incidence of anxiety or irritability was associated with the highest plasma levels. Our findings suggest that monitoring plasma DLX levels may be helpful in predicting better treatment responses and tolerability. The present data seem to suggest an optimal anxiolytic efficacy of DLX at intermediate plasma levels.

AB - Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor that has been recently approved for the treatment of major depressive disorder (MDD). However, little is known about the relationship between DLX plasma levels and clinical response. The aims of this open-label study were 1) to assess clinical outcome and tolerability of DLX by means of clinician and patient assessments and 2) to evaluate the value of plasma DLX levels as predictors of clinical response and tolerability. This was a naturalistic, open-label study of 45 outpatients affected with MDD (16 men and 29 women), who received DLX at doses of 30-120 mg/day and were evaluated at baseline (T0) and after 2, 4 and 12 weeks (T1-3). The assessments included the Hamilton Rating Scales for Depression (HRSD) and Anxiety (HRSA), Clinical Global Impression-Severity (CGI-S), Beckgs Depression Inventory (BDI) and a mood visual analogue scale (VAS). Compared with T0, there were significant improvements in HRSD at T1, T2 and T3 (P <0.001), in HRSA, CGI-S and the self-administered BDI at T2 and T3 (P <0.001), and in the VAS scores shown at T3 (P = 0.01). DLX treatment was safe and well tolerated. Plasma DLX levels at T2 ranged from 5 to 135 ng/mL (mean ± SD = 53.56 ± 39.45) and correlated almost significantly with the DLX dose (r = 0.35; P = 0.069). There was a significant curvilinear quadratic relationship between the improvement of HRSA scores and plasma DLX levels (R 2 = 0.27; P = 0.02). The incidence of anxiety or irritability was associated with the highest plasma levels. Our findings suggest that monitoring plasma DLX levels may be helpful in predicting better treatment responses and tolerability. The present data seem to suggest an optimal anxiolytic efficacy of DLX at intermediate plasma levels.

KW - clinical response

KW - duloxetine

KW - major depressive disorder

KW - plasma levels

UR - http://www.scopus.com/inward/record.url?scp=77955164450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955164450&partnerID=8YFLogxK

U2 - 10.1177/0269881109104863

DO - 10.1177/0269881109104863

M3 - Article

C2 - 19406851

AN - SCOPUS:77955164450

VL - 24

SP - 1193

EP - 1199

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 8

ER -